Glial Connexin-43 is a pathogenic mechanism promoting gut inflammation after postsurgical intestinal manipulation with potential relevance to humans.

Summary

This mechanistic study shows that enteric glial Connexin-43 drives inflammatory signaling, immune-cell activation, and enteric neuropathy after postsurgical intestinal manipulation. Genetic deletion or pharmacologic inhibition of glial Cx43 dampened IL-6/CCL2 release, reduced gliosis, and preserved neural integrity, with supportive human tissue data. Targeting glial Cx43 emerges as a plausible strategy to prevent postoperative ileus.

Key Findings

• Enteric glia highly express Connexin-43 in mice and humans and upregulate it after surgical stress and inflammation.
• Glial Cx43 deletion or peptide inhibition (43Gap26) reduced IL-6/CCL2 release, gliosis, immune activation, and prevented enteric neuropathy in mouse POI.
• Human surgical intestinal trauma samples showed Cx43 upregulation, supporting translational relevance.

Clinical Implications

Pharmacologic modulation of glial Cx43 could be tested to prevent or mitigate postoperative ileus after abdominal surgery, informing perioperative anti-inflammatory and neuroprotective strategies.

Limitations

• Preclinical models dominate; no randomized clinical trial evidence yet
• Peptide inhibitor translational pharmacokinetics and off-target effects not fully characterized

Future Directions

Early-phase clinical trials to evaluate safety and efficacy of Cx43 modulators for POI prevention; biomarker development (e.g., glial activation signatures) to identify high-risk patients.